Initial tests only where useful, depending on the presentation. Investigations must not delay suspected cancer pathway referral and are not a substitute for tissue diagnosis. Order in parallel, not sequentially.
FBC Β± film + CRP/ESR Unexplained lymphadenopathy
Consider FBC with differential/blood film and CRP or ESR according to the clinical picture and local pathway; do not delay suspected cancer referral while awaiting results. Consider a very urgent FBC (within 48 hours) if features suggest leukaemia (generalised lymphadenopathy, hepatosplenomegaly, unexplained bruising, bleeding, petechiae, persistent fatigue or unexplained fever β NICE NG12). Atypical lymphocytes β EBV; mature lymphocytosis β CLL; pancytopenia + LAP β marrow infiltration
LDH, urate, U&E, LFTs Selected patients
Not a diagnostic lymphoma screen. Consider LDH, urate, renal function and liver function in patients with substantial, widespread or rapidly progressive lymphadenopathy, systemic illness or suspected haematological malignancy, usually in discussion with the haematology pathway
Paul-Bunnell / monospot
If infectious mononucleosis is clinically suspected, use the local laboratory EBV testing pathway. Interpret early negative tests cautiously β a negative result does not exclude EBV. Consider FBC, liver enzymes and alternative diagnoses according to the presentation
TSH Β± FT4/FT3 Thyroid lump
TSH alone is generally the first test in adults (NICE NG145). If TSH raised, add FT4; if TSH suppressed, add FT4 and FT3. Ultrasound is not a generic thyroid test β it is indicated for palpable thyroid enlargement or focal nodularity when malignancy is suspected (NG145), using an established risk-stratification (U-grade) system with ultrasound-guided FNAC according to the result (NICE NG230), usually via the specialist/suspected cancer pathway. Don't delay referral waiting for TFTs
Chest X-ray Aged β₯40
Consider an urgent direct-access chest X-ray (within 2 weeks) for adults aged 40 and over with supraclavicular or persistent cervical lymphadenopathy (NICE NG12/local pathway), while considering suspected cancer referral on the wider clinical picture. May show mediastinal widening, hilar LAP or a lung primary
HIV test
Offer where clinically indicated (e.g. unexplained or generalised lymphadenopathy) or as part of local opt-out testing. Persistent generalised lymphadenopathy is a recognised HIV presentation
Mantoux / IGRA test
TB testing and referral only when epidemiology and clinical features support it (endemic country of origin, immunosuppression, TB contact). IGRA and Mantoux assess TB infection and do not exclude active TB (UKHSA). If tuberculous lymphadenitis is suspected, discuss urgently with the local TB service and pathology/microbiology team before sampling where possible. Diagnostic lymph-node aspirate or biopsy may be required; send specimens for histology, mycobacterial microscopy/culture and nucleic-acid amplification testing as advised (NICE NG33)
Do NOT order
Do not arrange CT, MRI, PET-CT or biopsy routinely for an unexplained neck lump if this would delay referral or duplicate the suspected cancer pathway β follow the local pathway; specialist teams usually arrange cross-sectional imaging and tissue diagnosis. Do not perform or arrange blind biopsy in primary care: tissue diagnosis should be image-guided via the head-and-neck, thyroid or haematology pathway (with microbiology, flow cytometry and/or mycobacterial studies as the specialist team advises if TB or lymphoma is possible). No tumour markers without indication